Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Videx EC · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Videx EC | DRUG | - |
| Epivir | DRUG | - |
| Sustiva | DRUG | - |
Inclusion Criteria: * Documented HIV infection * ≥ 18 years of age and weight at least 40kg * Two plasma HIV RNA levels \< 50 copies/mL during the qualification and screening period * Patients receiving a PI and ≥ 2 NRTIs Exclusion Criteria: * Pregnancy or breastfeeding * Documented virologic fai...
Top 20 of 28 competitors
Videx EC is used for HIV Infections. It is a small molecule being developed by Bristol-Myers Squibb Company for the treatment of HIV-1 infection. The drug is intended for patients with HIV, and it has been studied in a clinical trial involving patients with an undetectable viral load.
Videx EC targets HIV. It is an antiretroviral medication used in the treatment of HIV infections. The drug works by inhibiting the reverse transcriptase enzyme, which is essential for viral replication. This mechanism helps reduce the viral load in patients with HIV.
Videx EC is developed by Bristol-Myers Squibb Company, a pharmaceutical company listed on the stock exchange under the ticker symbol BMY. The company is responsible for the clinical development and manufacturing of this investigational drug for HIV infections.
Videx EC is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug is being studied for the treatment of HIV infections.
Videx EC has one completed Phase 3 clinical trial with the identifier NCT00135382. This trial studied switching HIV-1 infected patients with an undetectable viral load from a protease inhibitor-based regimen to an efavirenz-based regimen. The trial enrolled 254 participants in the United States and Puerto Rico.
Videx EC is a brand name for didanosine, an antiretroviral medication used to treat HIV infection. The drug is available in an enteric-coated formulation, which is designed to improve gastrointestinal tolerability. It is used as part of combination therapy for HIV.